Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) received an average rating of “Hold” from the fourteen rating agencies that currently cover the company, reports Marketbeat.com. One research analyst rated the stock with a sell recommendation, five gave the company a hold recommendation and four gave the company a buy recommendation. The 1-year average price target among brokers who have rated the stock in the past year is $52.51.
Several equity research analysts have weighed in on the company recently. Credit Suisse Group cut its price target on Fresenius Medical Care AG & Co. KGaA from €66.00 ($70.21) to €61.00 ($64.89) in a Tuesday, March 1 report. JPMorgan Chase & Co. raised its price target on Fresenius Medical Care AG & Co. KGaA from €48.70 ($51.81) to €51.00 ($54.26) and assigned the company a rating “underweight” in a Thursday, May 5, report. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from an “underperforming” rating to a “buy” rating and raised its price target for the company from $30.30 to $33.70 in a report released on Monday. Berenberg Bank cut its price target on Fresenius Medical Care AG & Co. KGaA from €84.90 ($90.32) to €83.40 ($88.72) in a Thursday, March 17 report. Finally, Truist Financial lowered its price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “holding” rating for the company in a Wednesday, June 22 research report. .
Several hedge funds have recently bought and sold shares of FMS. Ellevest Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 96.6% in the fourth quarter. Ellevest Inc. now owns 1,148 shares of the company worth $37,000 after acquiring an additional 564 shares in the last quarter. First PREMIER Bank increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 118.6% in the 4th quarter. First PREMIER Bank now owns 1,290 shares of the company worth $42,000 after acquiring an additional 700 shares in the last quarter. Tcwp LLC bought a new equity position in Fresenius Medical Care AG & Co. KGaA in Q1 for a value of approximately $44,000. SRS Capital Advisors Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 36.0% in the 1st quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company worth $52,000 after acquiring 409 additional shares in the last quarter. Finally, Creative Financial Designs Inc. ADV bought a new stock position in Fresenius Medical Care AG & Co. KGaA in Q1 for a value of approximately $67,000. 4.73% of the shares are held by hedge funds and other institutional investors.
FMS shares opened at $24.99 on Wednesday. The stock’s fifty-day moving average price is $29.11 and its two-hundred-day moving average price is $31.49. The company has a market capitalization of $14.65 billion, a PE ratio of 14.28, a P/E/G ratio of 1.03 and a beta of 1.17. Fresenius Medical Care AG & Co. KGaA has a fifty-two week minimum of $23.29 and a fifty-two week maximum of $42.13. The company has a debt ratio of 0.51, a quick ratio of 0.93 and a current ratio of 1.26.
Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last released its quarterly earnings data on Wednesday, May 4. The company reported earnings per share of $0.38 for the quarter, beating the consensus estimate of $0.30 by $0.08. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.99% and a net margin of 4.91%. The company posted revenue of $5.10 billion for the quarter, versus a consensus estimate of $4.97 billion. On average, stock analysts predict that Fresenius Medical Care AG & Co. KGaA will post an EPS of 1.93 for the current financial year.
The company also recently disclosed an annual dividend, which was paid on Friday, May 27. Shareholders of record on Monday, May 16 received a dividend of $0.7093. This represents a dividend yield of 3.4%. The ex-dividend date was Friday, May 13. The dividend payout ratio (DPR) of Fresenius Medical Care AG & Co. KGaA is currently 28.00%.
About Fresenius Medical Care AG & Co. KGaA (Get a rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Fresenius Medical Care AG & Co. KGaA right now?
Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.
While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here